In addition, Zhang et al22 showed that CXCL3 played a key role in humoral immune infiltration in the development of cirrhosis-related liver cancer.21 At present, there is no study on the relationship between MYO1E and liver cancer, but the study by Liu et al23 showed that MYO1E is mainly expressed in pancreatic adenocarcinoma (PAAD) and is negatively correlated with the survival and prognosis of patients.22 This is in line with the survival curve analysis outcomes for varying MYO1E expression, suggesting that MYO1E may serve as a useful therapeutic target in HCC. Here, CXCL3 is linked to liver cancer.